Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals’ General Counsel reports two stock sales. Kelley Shannon T, an officer of Madrigal Pharmaceuticals, reported selling 263 shares of common stock at $490.77 per share and 429 shares at $501.40 per share on 01/20/2026. The first transaction reflects shares sold by the company on the reporting person’s behalf solely to cover tax withholding tied to vesting restricted stock units and occurred automatically. The second sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2024. After these transactions, the reporting person directly owned 8,481 shares of Madrigal common stock.
Madrigal Pharmaceuticals insider files to sell common stock. A Form 144 notice indicates an intention to sell 263 shares of Madrigal Pharmaceuticals common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026 on the Nasdaq Stock Market. These shares were acquired on 01/16/2026 via a restricted stock unit grant that vested on the same date. The filing notes that Madrigal Pharmaceuticals had 22,711,420 shares of common stock outstanding. Over the past three months, the same seller disposed of 429 shares of common stock on 01/20/2026 for gross proceeds of 215100.6. The signer represents that they are not aware of undisclosed material adverse information about the company.
Madrigal Pharmaceuticals director Rebecca Taub reported an automatic sale of company stock primarily to cover taxes. On January 20, 2026, the issuer sold 2,238 shares of common stock on her behalf at $490.77 per share to satisfy tax withholding obligations tied to vesting restricted stock units, a process described as automatic and not at her discretion. Following this transaction, she directly held 453,351 shares of Madrigal Pharmaceuticals common stock. The filing also notes an additional 655,540 shares held indirectly through SQN LLC, an entity managed by Taub and her spouse, with Taub disclaiming beneficial ownership of those securities except to the extent of any pecuniary interest.
Madrigal Pharmaceuticals insider files a Form 144 notice for a planned stock sale. The filing covers a proposed sale of 2238 shares of Madrigal common stock through Morgan Stanley Smith Barney LLC on or about 01/20/2026, with an aggregate market value listed as 1122759.84 and 22711420 shares of common stock outstanding. The shares to be sold were acquired on 01/16/2026 via a restricted stock unit grant from the issuer, vesting the same day.
The notice also lists recent Rule 10b5-1 plan sales in the past three months. For Rebecca A. Taub, there were two sales of 18650 shares each on 12/10/2025 and 01/09/2026, with gross proceeds of 10297573.26 and 9749391.94. For Paul A. Friedman, there were two sales of 24800 shares each on the same dates, with gross proceeds of 13694158.24 and 12963304.72.
Madrigal Pharmaceuticals’ Chief Accounting Officer Rita Thakkar reported new equity awards. On January 15, 2026, she received 2,398 shares of common stock as a grant of restricted stock units at no cost. These units vest in four equal 25% installments on January 15 of 2027, 2028, 2029 and 2030, as long as she remains in service with the company on each vesting date.
She was also granted a stock option for 1,826 shares of common stock, likewise at no cost on the grant date. The option vests 25% of the shares on January 15, 2027, with the remaining 75% vesting in 6.25% increments on the last day of each successive three-month period, subject to continued service. After these grants, she directly holds 2,398 shares of common stock and 1,826 stock options.
Madrigal Pharmaceuticals, Inc. filed an initial ownership report for Chief Accounting Officer Rita Thakkar. The Form 3 states that no securities are beneficially owned, meaning the reporting person does not report holding any Madrigal common stock or derivative securities as of the event date. The filing is primarily administrative and does not describe any purchases, sales, or option grants.
Madrigal Pharmaceuticals insider files to sell 429 shares of common stock under Rule 144. The shares have an aggregate market value of $215,220.72 and are to be sold through Morgan Stanley Smith Barney LLC on or after an approximate sale date of 01/20/2026 on the NASDAQ exchange. The securities were acquired from the issuer on 01/16/2026 as restricted stock units, in the same amount of 429 shares. Madrigal Pharmaceuticals had 22,711,420 shares outstanding of common stock at the time referenced in the notice.
Madrigal Pharmaceuticals director Paul A. Friedman reported an option exercise and small share sale. On January 9, 2026, he exercised a stock option for 280 shares of common stock at $15.80 per share, then sold 280 shares of common stock at a weighted average price of $551.2414 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 10, 2025.
After these transactions, he directly owned 187,164 shares of Madrigal common stock. The filing also notes 655,540 shares held indirectly through SQN LLC, an entity for which he and his spouse are managing members, with a disclaimer that he only benefits to the extent of his pecuniary interest.
Madrigal Pharmaceuticals director Paul A. Friedman reported insider transactions in company common stock. On January 9, 2026, he exercised a fully vested stock option for 24,520 shares of common stock at an exercise price of $15.8 per share and then sold multiple small blocks of common stock the same day under a Rule 10b5-1 trading plan adopted on September 10, 2025. The reported sale prices are disclosed as weighted averages, with underlying trades occurring at prices generally ranging from about $511.71 to $545.79 per share. After these transactions, he directly held 187,164 shares of common stock and 280 stock options, and also reported 655,540 shares held indirectly through SQN LLC, for which he and his spouse are managing members.
Madrigal Pharmaceuticals director Rebecca Taub reported stock transactions dated 01/09/2026. She exercised a stock option for 240 shares of common stock at $15.80 per share and then sold 40 shares at $545.79 and 200 shares at a weighted average price of $551.242. These sales were made under a Rule 10b5-1 trading plan adopted on September 10, 2025. After the reported sales, she directly owned 455,589 shares of common stock. The filing also lists 655,540 shares held indirectly by SQN, LLC, an entity for which she and her spouse are managing members, and she disclaims beneficial ownership of those securities except to the extent of any pecuniary interest.